CLOs on the Move

Roswell Biotechnologies

www.roswellbiotech.com

 
Roswell Biotechnologies is a molecular electronics company transforming DNA sequencing with their latest platform, designed to deliver the disruptive performance required for future biomedical and industrial applications.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Diasome Pharmaceuticals Inc

Diasome Pharmaceuticals, Inc. is focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity.

Sinclair Research Center Inc

Sinclair Research Center Inc is a Columbia, MO-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Celgene

Celgene Corporation is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. Our talent, scientific knowledge and research capabilities help us to deliver access to innovative, disease-altering therapies to those who need them most. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies. Celgene is headquartered in Summit, New Jersey, and employs more than 7,000 people located in more than 60 countries.

Celula Inc

Celula Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Seattle Genetics

Targeting Cancer. Transforming Therapies. Revolutionary science meets transformative cancer therapy Seattle Genetics is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells. The largest global oncology biotechnology company based in the Pacific Northwest, we are focused on developing and commercializing a new generation of targeted, empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer. Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary technology, we are able to optimize each ADC to potentially improve outcomes for patients. ADCs are an integral part of the evolving cancer treatment paradigm with their specificity, stability and potency. In addition to one marketed product, we are advancing a strong product pipeline designed to address significant unmet medical needs.